N
Natera
Harnessing the power of DNA to improve the management of reproductive health, cancer, and organ transplants
At a glance
- Founded
- 2004
- Headquarters
- Austin, United States
- Listing
- IPO 2015
- Sector
- Biotech & Life Sciences
- Power Law
- Decacorn$10B+ valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Natera.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Sequoia- CVClaremont Creek Ventures
Series B and later11 investors entered at this stage
Foresite Capital
Founders Fund- HPHealthCor Partners
Franklin Templeton Investments- SISofinnova Investments
Lightspeed Venture Partners- ACAlafi Capital
- JAJennison Associates
- HPHarmony Partners
RA Capital Management
OrbiMed
Source: Dealroom Talent Intelligence.
Alumni founders
Former Natera employees who went on to found companies, sorted by Dealroom signal score.
DADatavantEst. 2017
Sam RooszUnited States
GIGigaGenEst. 2010
David JohnsonUnited States
Jonathan SheenaUnited States
CBCurve BiosciencesEst. 2021
Nathan HunkapillerUnited States
STSilverback TherapeuticsEst. 2016
Badreddin EdrisUnited StatesGlobal footprint
team presence
across markets
Patents
59 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Natera was the backer or acquirer, 2022–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
2 deals across Natera's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where Natera deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
Natera's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Natera on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Natera on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.